Regulatory Briefing · The Ledger
What the July 2026 FDA PCAC meeting means for your peptide access
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews seven peptides for the 503A approved bulks list. The outcome shapes which peptides compounding pharmacies can legally prepare — and therefore what you can get prescribed.
The stakes in one line
Peptides added to the 503A bulks list stay clearly available through compounding pharmacies. Those
left off face tighter restrictions — which can ripple through to telehealth prescribed access.The seven peptides under review
| Peptide | Common use | What's at stake |
|---|---|---|
| BPC-157 | Tissue & gut repair | Staff briefing proposes not adding to 503A bulks list |
| KPV | Anti-inflammatory | Under review for 503A consideration |
| TB-500 | Recovery | Under review |
| MOTS-C | Metabolic / mitochondrial | Under review |
| DSIP | Sleep | Under review (as Emideltide) |
| Semax | Cognitive | Under review |
| Epitalon | Longevity | Under review |
BPC-157 is the one to watch
A staff briefing proposes that BPC-157 not be added to the 503A approved bulks list. That wouldn't be an outright ban, but it would restrict how compounding pharmacies can prepare it — a meaningful change given BPC-157's popularity for tissue and gut repair. The committee's vote is advisory; the FDA makes the final determination.
What to do before July 24
- If you're already on a prescribed protocol, talk to your provider about continuity plans.
- Understand the difference between research-grade and prescribed pathways — see Research vs Prescribed.
- Check back here after July 24 — we'll publish outcome coverage as the votes land.
We'll cover the outcome
Veritide will publish results coverage within hours of the July 24 vote, including what each decision
means for prescribed access. Bookmark The Ledger.FAQ
What is the FDA PCAC meeting?
The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk drug substances may be used in 503A compounding. The July 23–24, 2026 meeting reviews seven peptides for the approved bulks list — a decision that shapes which peptides compounding pharmacies can legally prepare.
Will BPC-157 be banned?
Not exactly. A staff briefing proposes BPC-157 not be added to the 503A approved bulks list, which would restrict how compounding pharmacies can prepare it — different from an outright ban. The committee's recommendation is advisory; the FDA makes the final call.
How does this affect getting peptides prescribed?
If a peptide isn't on the 503A bulks list, compounding pharmacies face tighter limits on preparing it, which can reduce prescribed access through telehealth providers. We'll publish outcome coverage after the July 24 vote.
Deeper science
For the mechanism and research behind BPC-157 and the other peptides under review, see
PeptideOnline.Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.